2025-09-10 15:57:39

Novo Nordisk: Oral semaglutide for obesity is under review by the U.S. Food and Drug Administration (FDA), and the announcement about layoffs does not affect the application.
Email Subscription
Newsletters and emails are now available! Delivered on time, every weekday, to keep you up to date with North American business news.
ASIA TECH WIRE

Grasp technology trends

Download